Astrazeneca Pharma India Ltd vs Rekvina Labs Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8308 as of 12 May 15:30 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 80.7 on March 2021 to 185.9 on March 2025 . This represents a CAGR of 18.16% over 5 yearsThe P/E Ratio of Rekvina Labs Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 7525 crore on March 2021 to ₹ 21515 crore on March 2025 . This represents a CAGR of 23.38% over 5 yearsThe Market Cap of Rekvina Labs Ltd changed from ₹ 2.39 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 5 years The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 618.18 crore as compare to the Sep '25 revenue of ₹ 565.26 crore. This represent the growth of 9.36% The revenue of Rekvina Labs Ltd for the Dec '25 is ₹ 0.35 crore as compare to the Sep '25 revenue of ₹ 0.2 crore. This represent the growth of 75% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 51.44 crore as compare to the Sep '25 ebitda of ₹ 76.06 crore. This represent the decline of -32.37% The ebitda of Rekvina Labs Ltd for the Dec '25 is ₹ -0.12 crore as compare to the Sep '25 ebitda of ₹ -0.03 crore. This represent the growth of 300% The net profit of Astrazeneca Pharma India Ltd changed from ₹ -11.79 crore to ₹ 32.59 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Rekvina Labs Ltd changed from ₹ -0.07 crore to ₹ -0.12 crore over 6 quarters. This represents a CAGR of 43.24% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Rekvina Labs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Rekvina Labs Ltd

Rekvina Labs Limited was incorporated on 1st November 1988.
From a small domestic company at inception in middle of 80's, Rekvina has grown formidably to be an integrated, Indian pharmaceutical company with sales in excess of Rs 20 Crore.
It is registered in England and Wales as a Public Limited Company.
The Company is a Quality producer of Pharmaceutical formulations for its customer as per their specific requirements.
It provide contract research and manufacturing services to customers. The Company is mainly engaged in manufacturing and marketing of pharmaceutical products.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Rekvina Labs Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Rekvina Labs Ltd?

Market cap of Astrazeneca Pharma India Ltd is 21,347 Cr while Market cap of Rekvina Labs Ltd is 22 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Rekvina Labs Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Rekvina Labs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Rekvina Labs Ltd?

As of May 12, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8538.85. On the other hand, Rekvina Labs Ltd stock price is INR ₹37.22.

How do dividend payouts of Astrazeneca Pharma India Ltd and Rekvina Labs Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Rekvina Labs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.